重症疟疾最优治疗与青蒿素耐药威胁
该研究扩展药代动力学/药效学建模方法,模拟10000例重症疟疾患者的治疗,追踪隔离寄生虫所致病理。模型重现了既有研究基于循环寄生虫的临床结局,显示简化青蒿琥酯方案在总体人群中不劣于世界卫生组织现有方案,但在感染集中于寄生虫生命周期早期的患者亚组中结局更差,且该亚组对寄生虫早期环状体阶段出现的耐药极为脆弱。
要点
- 简化青蒿琥酯方案总体不劣于世界卫生组织现有方案,但早期环状体感染亚组结局更差。
- 现有临床试验以循环寄生虫清除率为结局,与重症疟疾病理主要源于隔离寄生虫之间存在脱节。
- 寄生虫早期环状体阶段的青蒿素耐药对重症疟疾治疗构成紧迫威胁。
核心结论
- 简化青蒿琥酯方案在总体人群中不劣于世界卫生组织现有方案,但在感染集中于寄生虫生命周期早期的患者亚组中结局更差。
- 寄生虫早期环状体阶段出现的青蒿素耐药对重症疟疾治疗构成紧迫威胁。
研究设计与样本
- 研究扩展既有药代动力学/药效学建模方法,模拟10000例重症疟疾患者的治疗,并追踪隔离寄生虫所致病理。
主要发现
- 模型重现了既有研究基于循环寄生虫的临床结局。
- 简化青蒿琥酯方案在总体患者人群中不劣于世界卫生组织现有方案。
- 简化方案在感染集中于寄生虫生命周期早期的患者亚组中结局更差。
- 该亚组患者对寄生虫早期环状体阶段出现的耐药极为脆弱。
临床怎么用
- 提示评估重症疟疾治疗方案时需关注隔离寄生虫所致病理,而非仅以循环寄生虫清除率为结局。
- 对感染集中于寄生虫生命周期早期的患者,应警惕简化青蒿琥酯方案的较差结局与早期环状体耐药风险。
局限性
- 结论基于药代动力学/药效学建模模拟,而非直接临床试验观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard treatment for severe malaria is with artesunate; patient survival in the 24 hours immediately posttreatment is the key objective. Clinical trials use clearance rates of circulating parasites as their clinical outcome, but the pathology of severe malaria is attributed primarily to noncirculating, sequestered, parasites, so there is a disconnect between existing clinical metrics and objectives. METHODS: We extend existing pharmacokinetic/pharmacodynamic modeling methods to simulate the treatment of 10000 patients with severe malaria and track the pathology caused by sequestered parasites. RESULTS: Our model recovered the clinical outcomes of existing studies (based on circulating parasites) and showed a "simplified" artesunate regimen was noninferior to the existing World Health Organization regimen across the patient population but resulted in worse outcomes in a subgroup of patients with infections clustered in early stages of the parasite life cycle. This same group of patients were extremely vulnerable to resistance emerging in parasite early ring stages. CONCLUSIONS: We quantify patient outcomes in a manner appropriate for severe malaria with a flexible framework that allows future researchers to implement their beliefs about underlying pathology. We highlight with some urgency the threat posed to treatment of severe malaria by artemisinin resistance in parasite early ring stages.
引用
- Jones S, Hodel EM, Sharma R, et al. Optimal Treatments for Severe Malaria and the Threat Posed by Artemisinin Resistance. J Infect Dis. 2019. PMID: 30517708. doi:10.1093/infdis/jiy649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。